Anavex Life Sciences Corp (AVXL)

[ckent]

It was good to be able to go back and watch the MSQ Ventures video. Both Missling and the interviewer did a great job on this. I particularly liked the two minutes beginning at min 17 where Missling sums up our P3 Alzheimer's results directly comparing them to Biogen's Lecanumab.

1) The signal of 273 was stronger than the antibody approved by the FDA called Lecanumab, and not only that, but
2) the improvement was seen a half year earlier than Lecanumab, and not only that, but
3) Blarcamesine is easier to administer than Lecanumab, taken orally once daily before bed, and not only that, but
4) there are no adverse events, unlike Lecanumab.

Missling makes it clear that the FDA has set Lecanumab as the bar and we easily clear it.

Can't wait for all the bulletproof details from Dr. Kun Jin!